Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.4.21.1 (chymotrypsin)
 10,938 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The current study examines the effects of alpha-difluoromethylornithine (DFMO), an irreversible ornithine decarboxylase inhibitor, on pancreatic growth and development of rat neonates. Newborn rats were given daily subcutaneous injections of 300 or 500 mg kg-1 DFMO and killed after 7, 14, 21, and 28 days of treatment. Pancreatic weights and DNA, RNA, protein, amylase and chymotrypsin total contents (per pancreas) and concentrations were evaluated at the end of each period. Inhibition of body weight gain (30%) was maximal after 14 days of the 500 mg DFMO treatment. Pancreatic weight increase of 20% was significant after 7 days of the 300 mg DFMO treatment while deficits of 15, 20, and 14% were significant after 21 days of 300 mg DFMO and 14 and 21 days of 500 mg DFMO. Total DNA was already subnormal after one week of 500 mg DFMO with a maximal reduction of 30% after 28 days while a significant decrease of 15% was observed only after 3 weeks of 300 mg DFMO. Pancreatic hypertrophy was observed after 7 and 28 days of the 500 mg and after 14 days of the 300 mg DFMO treatment. Chymotrypsin total contents and concentrations were always preferentially affected over those of amylase. These data support the view that ornithine decarboxylase (ODC) and polyamines play an important role in cell replication and growth of the pancreatic tissue during the neonatal period.
Pancreas 1987
PMID:Implication of ornithine decarboxylase and polyamines in pancreatic growth of neonatal rats. 311 41

We have studied the degree of pancreatic secretory alterations assessed by secretin-cerulein test (S-C) in relation to various morphological changes detected by real-time ultrasonography (US) in 42 patients affected by chronic pancreatitis. Exocrine insufficiency was found in 41 patients (97.6%), while morphological alterations were detected in 32 (76.1%). In the 10 patients with normal US, a mild or moderate exocrine insufficiency was present. Significant negative linear correlations of decreasing volumes of duodenal aspirate (r = 0.528, p less than 0.001) and output of bicarbonate (r = 0.635, p less than 0.001), lipase (r = 0.583, p less than 0.001), and chymotrypsin (r = 0.592, p less than 0.001) were found with increasing ultrasonographic alterations. However, a wide overlap was found in the secretory behavior in the various categories of change as determined by ultrasound. Hence, the attempt to predict exocrine function on the basis of morphological alterations proved unsuccessful.
Pancreas 1987
PMID:Relationship between morphological changes detected by ultrasonography and pancreatic exocrine function in chronic pancreatitis. 330 60

In the present study an improved method of reversed-phase high-performance liquid chromatography (HPLC) for separation of rat pancreatic juice proteins is introduced. Aliquots of pancreatic juice were saved from conscious rats during basal secretion. The secretory proteins were separated on a wide-pore silica column by use of a multistep acetonitrile/water gradient. Up to 14 individual peaks could be separated by one run. Molecular weight analysis by sodium dodecyl sulfate (SDS)-gels allowed identification of peaks representing amylase, lipase, procarboxypeptidases, proelastase, chymotrypsinogen, and trypsinogen. Injection of pure rat amylase increased one specific peak which was assumed to represent amylase in the juice profile. Small amounts of residual enzymatic activities were measured for amylase, trypsin, and chymotrypsin in material of certain peaks. Activities of lipase, ribonuclease, and carboxypeptidases were not found, which reflected degradation of these enzymes by the separation procedure. High activities of phospholipase A2 were detected in one specific, early-eluting peak. Reversed-phase HPLC offers precise, reproducible, and rapid separation of the major proteins of rat pancreatic juice.
Pancreas 1988
PMID:Identification of rat pancreatic secretory proteins after separation by high-performance liquid chromatography. 337 29

The study evaluates two methods of assay of fecal chymotrypsin (titrimetric and spectrophotometric method) as an index of exocrine pancreatic function. The assay was performed on 101 control subjects and 128 cystic fibrosis (CF) patients by the first method, and 75 controls and 102 CF patients by the second method. CF subjects were subdivided into four groups based on pancreatic function: total pancreatic insufficiency in the first group, partial pancreatic insufficiency in the second group, normal pancreatic function in the third group, and pancreatic insufficiency plus enzymatic treatment in the fourth group. Fifty-four CF patients were examined in the first group, 27 in the second group, 19 in the third group, and 28 in the fourth group by the titrimetric method; 23, 25, 50, and 65, respectively by the spectrophotometric method. The spectrophotometric method was highly reproducible and more sensitive and specific. With such a method the assay on stool random sampling correlated with the duodenal output of chymotrypsin after hormonal stimulation as well as fecal output of 72 h. The test had sensitivity and specificity of 100% if referred to CF patients with total pancreatic insufficiency. It was calculated that CF patients with normal fecal chymotrypsin have a probability of 76% to have a normal pancreatic function and a probability of 24% to have a partially compromised pancreatic function. The assay separates distinctly CF patients with a fat absorption coefficient greater than 90% from those with a coefficient less than 90%. The test is proposed for current clinical use in diagnosis and treatment of pancreatic insufficiency in cystic fibrosis.
Pancreas 1988
PMID:The assay of chymotrypsin in stool as a simple and effective test of exocrine pancreatic activity in cystic fibrosis. 338 19

To study the effects of chronic bombesin on pancreatic growth and secretion, rats were injected subcutaneously, 3 times daily for 4 days with either saline or bombesin (10 micrograms/kg). Bombesin significantly increased the pancreatic weight and content in protein and RNA but not in DNA. The ratios of the three former parameters to DNA increased, suggesting cellular hypertrophy. The pancreatic content in enzymes was also elevated, especially for chymotrypsin and to a lesser degree for amylase. However, the volume of pancreatic secretion and the output of enzymes in response to CCK under a continuous infusion of secretin remained unchanged. The in vitro secretory response to caerulein and bombesin was reduced for amylase and lipase. It is concluded that chronic bombesin exerts a trophic action on the rat pancreas but decreases the sensitivity of each cell to hormonal stimulation.
Pancreas 1987
PMID:Influence of repeated administration of bombesin on rat pancreatic secretion. 343 3

The present investigation provides follow-up data (up to 36 months) of exocrine and endocrine pancreatic function, inflammatory activity, pain, and body weight in 23 chronic pancreatitis patients submitted to Whipple's procedure plus intraoperative Ethibloc occlusion of the remaining pancreatic duct system between January 1983 and February 1984. Clinically, Whipple's procedure plus intraoperative pancreatic duct occlusion resulted in almost complete and continuous cessation of pain as well as significant (p less than 0.05) increase in body weight. With regard to exocrine pancreatic function (Secretin-Pancreozymin test, plasma amino acid consumption test, Pankreolauryl test, fecal chymotrypsin determination), intraoperative pancreatic duct occlusion was shown to induce high-grade insufficiency and thus exocrine parenchymal atrophy in all patients. Simultaneously, the inflammatory process (represented by serum levels of trypsin, lipase, and pancreatic isoamylase) was terminated in all 23 patients. Endocrine pancreatic function, evaluated by serum levels of insulin and C-peptide measured under fasting conditions and subsequent maximal combined beta-cell stimulation as well as corresponding integrated hormone releases, was reduced by partial pancreas resection by about 50%, while there was no further impairment during the 36-month follow-up period in consequence of additional intraoperative pancreatic duct occlusion. Altogether, Whipple's procedure plus intraoperative Ethibloc occlusion of the residual pancreatic duct system seems suitable for termination of the inflammatory process and thus preservation of residual endocrine pancreatic function in chronic pancreatitis.
Pancreas 1987
PMID:Whipple's procedure plus intraoperative pancreatic duct occlusion for severe chronic pancreatitis: clinical, exocrine, and endocrine consequences during a 3-year follow-up. 343 10

Bentiromide (N-benzoyl-L-tyrosyl-p-aminobenzoic acid; Bz-Tyr-PABA) is a useful agent in the assessment of exocrine pancreatic function. Bz-Tyr-PABA is hydrolyzed by chymotrypsin in the intestine with liberation of PABA and its metabolic products, arylamines. This study was undertaken to determine the normal values for absorption and excretion of arylamines in normal volunteers and in alcoholics without detectable disorders of the pancreas, liver, or small intestine. After an overnight fast, basal blood and urine samples for baseline arylamine levels were collected, followed by oral administration of 500 mg of bentiromide. A 6-h urine collection was instituted, and 90- and 120-min plasma samples were obtained. The results were analyzed comparing normals and alcoholics: The mean concentration of arylamines was significantly higher in alcoholics than nonalcoholic subjects in baseline urine and in plasma at 90 and 120 min; no significant difference was found between alcoholics and nonalcoholics when comparing mean arylamine levels in 6-h urines. In summary, cumulative 6-h urine arylamine levels are more reliable as a criterion than 90- and 120-min plasma levels in the assessment of exocrine pancreatic function in alcoholics.
Pancreas 1986
PMID:A new criterion in the assessment of bentiromide as a test of exocrine pancreatic function in alcoholics. 349 93

The bentiromide test reliably detects exocrine pancreatic insufficiency. The synthetic peptide attached to p-aminobenzoic acid (PABA) is cleaved by chymotrypsin, PABA is absorbed in the small intestine, partially conjugated in the liver, and excreted in the urine. It has been claimed that the bentiromide test is abnormal not only in patients with pancreatic insufficiency but also in patients with small bowel or liver disease because of impaired PABA absorption or conjugation, respectively. This study prospectively evaluates the bentiromide test in 12 patients with small bowel disease and 18 patients with biopsy-proven liver disease. One of 30 patients had an abnormal bentiromide test. Cumulative 6-h urinary arylamine excretion and plasma PABA concentration, 2 h after administration, were in the same range as healthy controls. We conclude that the bentiromide test is not affected by small bowel or liver disease. An abnormal test is virtually diagnostic for exocrine pancreatic insufficiency.
Pancreas 1987
PMID:Bentiromide test is not affected in patients with small bowel disease or liver disease. 349 95

Plasma concentrations of cholecystokinin (CCK) have been reported to be elevated in patients with chronic pancreatitis. The elevations are suggested to be due to increased release of CCK from the upper small intestine secondary to the absence of protease activity (trypsin and chymotrypsin) in the intestinal lumen. We have studied plasma CCK levels before and after liquid as well as solid meals in eight patients with pancreatic insufficiency due to advanced chronic pancreatitis and in eight healthy controls. CCK concentrations were measured with a sensitive and specific radioimmunoassay using an antibody directed against the sulfated tyrosyl region of CCK. No differences in basal or maximal postprandial plasma CCK levels between patients and controls were observed. In the liquid meal study, basal CCK concentrations in patients and controls were 2.2 +/- 0.7 and 2.5 +/- 0.4 pM, respectively, with maximal postprandial concentrations of 9.6 +/- 2.2 and 11.2 +/- 1.4 pM. In the solid meal study, basal CCK concentrations in patients and controls were 2.5 +/- 0.6 and 2.6 +/- 0.4 pM, respectively, with maximal postprandial concentrations of 9.4 +/- 1.6 and 8.6 +/- 1.4 pM. The only difference observed was a significantly longer time interval to maximal plasma CCK levels in patients as compared with controls after the liquid meal. Two patients with no detectable trypsin activity in the small intestinal lumen during a Lundh test meal had basal CCK levels of 1.3 and 1.8 pM. Thus, the present study does not support the hypothesis that trypsin is involved in the regulation of CCK release.(ABSTRACT TRUNCATED AT 250 WORDS)
Pancreas 1986
PMID:Plasma cholecystokinin concentrations in patients with advanced chronic pancreatitis. 356 43

Slaframine (SF), 1-acetoxy-6-aminooctahydroindolizine a parasympathomimetic with a high affinity for the gastrointestinal tract, was administered by oral intubation daily to 240 broiler chicks at either 0, 8.9, or 17.8 micrograms/kg body weight.75 (BW.75) in saline for 21 days. Throughout the experimental period weight, feed intake, and fecal output were measured. On Day 21 birds were killed, eviscerated, and wet organ weights were obtained. Pancreas and small intestine digesta were homogenized with saline and frozen for analyses of trypsin, chymotrypsin, amylase, and lipase activity as well as total protein. Weight, feed intake and utilization, pancreatic weight, liver weight, and small intestine digesta weight were not affected by SF treatment. Protein content of the digesta decreased 16.6% with the 17.8 micrograms SF/kg BW.75 treatment. Digesta lipase activity was 13.3% (P greater than .05) and specific activity 24% less (P less than or equal to .02) in 17.8 micrograms/kg BW.75 treated birds in comparison with those of controls, and activities decreased in a linear fashion across treatment levels (P less than or equal to .04). Digesta trypsin-specific activity decreased linearly with SF treatment (P less than or equal to .05), averaging 5.5 to 16.9% lower than control treated birds. Pancreatic chymotrypsin-specific activity was not significantly different among treatments. These results suggest that relatively small dosages of SF may affect digestive function of broiler chicks.
 ...
PMID:Effects of chronic administration of slaframine on production and digestive function in broiler chicks. 358 4


<< Previous 1 2 3 4 5 6 Next >>